All Vertex articles
-
BusinessThis little Crispr went to market
Gene editing technology heading towards commercial reality in pharmaceuticals, food and organ transplant
-
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
Vertex to cut 370 jobs
Imminent competition drives drop in its hepatitis C drug’s performance
-
Business
New cystic fibrosis drug in EU
Ivacaftor works by helping defective proteins function more normally